Your SlideShare is downloading. ×
0
3 Humongous Health-Care
Stocks This Week
A lot of health-care stocks
took a beating this week.
Not all of them, though.
Here are the three most
humongous health-ca...
Shares of the biopharmaceutical firm soared 22% this week.
Agios Pharmaceuticals (Nasdaq: AGIO)
Source: Yahoo! Finance
• Positive phase 1 preliminary data was
announced for cancer drug AG-221.
• Agios reported AG-221 was well
tolerated but w...
Shares of the biotech climbed 18% higher for the week.
Questcor Pharmaceuticals (Nasdaq: QCOR)
Source: Yahoo! Finance
• Specialty pharmaceutical
company Mallinckrodt (NYSE:
MNK) is acquiring Questcor.
• Shareholders will receive $30 in
cash...
Shares of the clinical-stage biotech jumped nearly 18% this week.
Bio-Path Holdings (Nasdaq: BPTH)
Source: Yahoo! Finance
• No big announcements this week
from Bio-Path.
• The biotech looks to be
rebounding from a sell-off that
started in late ...
• Questcor won’t shoot up significantly, since the
price of the acquisition by Mallinckrodt is set.
• Bio-Path Holdings co...
Find out which stock The Motley Fool’s chief
investment officer selected as the top pick for
2014 in our free report!
Upcoming SlideShare
Loading in...5
×

3 Humongous Healthcare Stocks This Week 4-11-14

5,423

Published on

This week's biggest health-care stocks

Published in: Healthcare, Business
0 Comments
3 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
5,423
On Slideshare
0
From Embeds
0
Number of Embeds
11
Actions
Shares
0
Downloads
5
Comments
0
Likes
3
Embeds 0
No embeds

No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849
  • Transcript of "3 Humongous Healthcare Stocks This Week 4-11-14"

    1. 1. 3 Humongous Health-Care Stocks This Week
    2. 2. A lot of health-care stocks took a beating this week. Not all of them, though. Here are the three most humongous health-care stocks over the week ending April 11, 2014.
    3. 3. Shares of the biopharmaceutical firm soared 22% this week. Agios Pharmaceuticals (Nasdaq: AGIO) Source: Yahoo! Finance
    4. 4. • Positive phase 1 preliminary data was announced for cancer drug AG-221. • Agios reported AG-221 was well tolerated but with two possible drug- related severe adverse events. • Clinical results were promising, with multiple complete remissions in patients with blood cancer. • Celgene (Nasdaq: CELG) stands as another winner, as AG-221 is part of a collaboration established between the big biotech and Agios in 2010. Why Agios shares took off
    5. 5. Shares of the biotech climbed 18% higher for the week. Questcor Pharmaceuticals (Nasdaq: QCOR) Source: Yahoo! Finance
    6. 6. • Specialty pharmaceutical company Mallinckrodt (NYSE: MNK) is acquiring Questcor. • Shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each Questcor share they own. • The deal represents a 27% premium over Questcor’s closing price before the announcement. Why Questcor shot up
    7. 7. Shares of the clinical-stage biotech jumped nearly 18% this week. Bio-Path Holdings (Nasdaq: BPTH) Source: Yahoo! Finance
    8. 8. • No big announcements this week from Bio-Path. • The biotech looks to be rebounding from a sell-off that started in late February. • Bio-Path’s Liposomal Grb-2 is in phase 1 clinical studies targeting several forms of leukemia and myelodysplastic syndrome. Why Bio-Path boomed
    9. 9. • Questcor won’t shoot up significantly, since the price of the acquisition by Mallinckrodt is set. • Bio-Path Holdings could continue its rebound, but major new developments are still in the future. • Agios’ early-stage results for AG-221 show considerable promise . • The partnership with Celgene gives Agios a leg up in continued development of the blood cancer drug. • A possibility also exists that Celgene could use some of its $5.6 billion in cash and short-term investments to scoop up Agios down the road. Best pick to stay humongous?
    10. 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×